Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.1
2.4
Journals
Medicina
Special Issues
GLP-1 and GIP Receptor Agonists, Cardiometabolic Disease, Oxidative Stress and...
share announcement

GLP-1 and GIP Receptor Agonists, Cardiometabolic Disease, Oxidative Stress and Dementia: Novel Insights and Challenges

A special issue of Medicina (ISSN 1648-9144).

Deadline for manuscript submissions: 31 May 2026 | Viewed by 1058

Special Issue Editor

Dr. George Pavlidis

E-Mail Website
Guest Editor
4th Department of Internal Medicine, Attikon University Hospital, National and Kapodistrian University of Athens, 12462 Athens, Greece
Interests: endothelial function; arterial stiffness; left ventricular myocardial function; atherosclerosis; oxidative stress; diabetes; cardiometabolic disease
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues, 

Cardiometabolic disease, namely metabolic disorders such as obesity and type 2 diabetes coupled with hypertension, atherosclerotic cardiovascular disease, heart failure, chronic kidney disease, and metabolic dysfunction-associated steatotic liver disease, has been linked to increased dementia risk. This association is mediated by shared metabolic, inflammatory, and several other neurobiological processes that contribute to cognitive decline. Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists show significant promise as a novel therapeutic approach for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and other cognitive disorders, by targeting cardiometabolic dysfunction, reducing oxidative stress and neuroinflammation, and improving cognitive function.

This Special Issue aims to highlight the latest pharmacological advancements and evidence-based clinical strategies for the optimal management of cardiometabolic disease and dementia syndromes.

We invite clinicians, researchers, and experts in cardiovascular medicine, internal medicine, endocrinology, and neurology to contribute original research articles, narrative and systematic reviews, or meta-analyses that focus on new insights into the beneficial mechanisms of GLP-1 and GIP receptor agonists on cardiometabolic disease and cognitive impairment, enhancing patient care and outcomes in these interconnected conditions.

Dr. George Pavlidis
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • glucagon-like peptide-1
  • glucose-dependent insulinotropic polypeptide
  • cardiometabolic disease
  • diabetes
  • hypertension
  • stroke
  • metabolic dysfunction-associated steatotic liver disease
  • oxidative stress
  • dementia

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

15 pages, 911 KB  
Article
Vascular and Myocardial Function in Patients with Type 2 Diabetes and Ischemic Stroke Treated with Dulaglutide or Empagliflozin
by George Pavlidis, Vasiliki Prentza, Ignatios Ikonomidis, Konstantinos Katogiannis, Aikaterini Kountouri, John Thymis, Eleni Michalopoulou, Loukia Pliouta, Emmanouil Korakas, Maria-Ioanna Stefanou, Lina Palaiodimou, Georgios Tsivgoulis and Vaia Lambadiari
Medicina 2026, 62(2), 254; https://doi.org/10.3390/medicina62020254 - 25 Jan 2026
Viewed by 751
Abstract
Background and Objectives: Patients with type 2 diabetes mellitus (T2DM) and ischemic stroke present with endothelial, vascular and left ventricular (LV) myocardial dysfunction. We investigated the effects of treatment with either glucagon-like peptide-1 receptor agonists (GLP-1RA) or sodium-glucose contrasporter-2 inhibitors (SGLT-2i) on endothelial [...] Read more.
Background and Objectives: Patients with type 2 diabetes mellitus (T2DM) and ischemic stroke present with endothelial, vascular and left ventricular (LV) myocardial dysfunction. We investigated the effects of treatment with either glucagon-like peptide-1 receptor agonists (GLP-1RA) or sodium-glucose contrasporter-2 inhibitors (SGLT-2i) on endothelial glycocalyx, arterial stiffness, and LV myocardial strain in patients with metformin-treated T2DM and a prior ischemic stroke. Materials and Methods: A total of 54 consecutive patients with T2DM and ischemic stroke who attended a cardiometabolic outpatient clinic in Athens, Greece, and received either GLP-1RA (dulaglutide; n = 27) or SGLT-2i (empagliflozin; n = 27) were enrolled in the study. We measured the perfused boundary region (PBR) of the sublingual microvessels, a marker of glycocalyx thickness, as well as carotid-femoral pulse wave velocity (PWV) and LV global longitudinal strain (GLS), at baseline and at 4 and 12 months of treatment. Results: Twelve months after treatment, all patients had reduced glycosylated hemoglobin and body mass index (BMI) (p < 0.001). Patients treated with dulaglutide showed a greater reduction in BMI (−11.8% vs. −4.8%, p < 0.001) compared to those treated with empagliflozin. Compared to baseline, all patients had reduced PBR, PWV and GLS (p < 0.001) after 12 months of treatment. However, empagliflozin presented a greater decrease in PWV (−14% vs. −10.9%, p = 0.041), while dulaglutide resulted in a greater increase in GLS (14.7% vs. 8.3%, p = 0.024) compared to empagliflozin. In all patients, the reduction in PBR at 12 months was correlated with a decrease in PWV and with an increase in GLS (p < 0.05). Conclusions: Both dulaglutide and empagliflozin improve cardiovascular function in T2DM patients with ischemic stroke. Dulaglutide appears to be more effective in the improvement of LV myocardial strain, whereas empagliflozin is more effective in reducing arterial stiffness. Full article
(This article belongs to the Special Issue GLP-1 and GIP Receptor Agonists, Cardiometabolic Disease, Oxidative Stress and Dementia: Novel Insights and Challenges)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop